| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lukas Andereggen, Marie-Luise Mono, Frauke Kellner-Weldon, Emanuel Chris. Cluster headache and macroprolactinoma: Case report of a rare, but potential important causality. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 40. 2017-12-22. PMID:28209309. |
headache associated with hyperprolactinemia has been reported to be responsive to dopamine agonists (da agonists) in many patients. |
2017-12-22 |
2023-08-13 |
Not clear |
| Rahim Khorassanizadeh, Vishnu Sundaresh, Steven N Levin. Primary Hypothyroidism with Exceptionally High Prolactin-A Really Big Deal. World neurosurgery. vol 91. 2017-09-28. PMID:27155380. |
this combination of hyperprolactinemia and pituitary gland enlargement might raise suspicion for a prolactinoma or a nonfunctioning adenoma limiting the ability of hypothalamic dopamine to inhibit prolactin production, the so-called "stalk effect." |
2017-09-28 |
2023-08-13 |
Not clear |
| Rosemary S E Brown, Ilona C Kokay, Hollian R Phillipps, Siew Hoong Yip, Papillon Gustafson, Amanda Wyatt, Caroline M Larsen, Penelope Knowles, Sharon R Ladyman, Paul LeTissier, David R Gratta. Conditional Deletion of the Prolactin Receptor Reveals Functional Subpopulations of Dopamine Neurons in the Arcuate Nucleus of the Hypothalamus. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 36. issue 35. 2017-08-17. PMID:27581458. |
in contrast, prlr deletion from all dopamine neurons resulted in profound hyperprolactinemia. |
2017-08-17 |
2023-08-13 |
mouse |
| David J Lyons, Rachida Ammari, Arash Hellysaz, Christian Broberge. Serotonin and Antidepressant SSRIs Inhibit Rat Neuroendocrine Dopamine Neurons: Parallel Actions in the Lactotrophic Axis. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 36. issue 28. 2017-07-18. PMID:27413150. |
these findings indicate that ssris may inhibit neuroendocrine dopamine release through both 5-ht-dependent and -independent actions, providing a mechanistic explanation for, and potential molecular targets for the amelioration of, the hyperprolactinemia and sexual dysfunction associated with these drugs. |
2017-07-18 |
2023-08-13 |
rat |
| Emmanuelle Kuhn, Philippe Chanso. Cabergoline in acromegaly. Pituitary. vol 20. issue 1. 2017-07-10. PMID:28025719. |
cabergoline, now the preferred dopamine agonist for treating hyperprolactinemia, is also used off-label for treating acromegaly. |
2017-07-10 |
2023-08-13 |
Not clear |
| William M Drake, Craig E Stiles, John S Bevan, Niki Karavitaki, Peter J Trainer, D Aled Rees, Tristan I Richardson, Stephanie E Baldeweg, Nemanja Stojanovic, Robert D Murray, Andrew A Toogood, Niamh M Martin, Bijay Vaidya, Than S Han, Rick P Steeds, F C Baldeweg, U E Sheikh, N Kyriakakis, S K Parasuraman, L Taylor, N Butt, S Anyia. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. The Journal of clinical endocrinology and metabolism. vol 101. issue 11. 2017-06-30. PMID:27571182. |
uncertainty exists whether the long-term use of ergot-derived dopamine agonist (da) drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease and whether current regulatory authority guidelines for echocardiographic screening are clinically appropriate. |
2017-06-30 |
2023-08-13 |
Not clear |
| Guillermina María Luque, Felicitas Lopez-Vicchi, Ana María Ornstein, Belén Brie, Catalina De Winne, Esteban Fiore, Maria Inés Perez-Millan, Guillermo Mazzolini, Marcelo Rubinstein, Damasia Becu-Villalobo. Chronic hyperprolactinemia evoked by disruption of lactotrope dopamine D2 receptors impacts on liver and adipocyte genes related to glucose and insulin balance. American journal of physiology. Endocrinology and metabolism. vol 311. issue 6. 2017-06-26. PMID:27802964. |
chronic hyperprolactinemia evoked by disruption of lactotrope dopamine d2 receptors impacts on liver and adipocyte genes related to glucose and insulin balance. |
2017-06-26 |
2023-08-13 |
mouse |
| Laura D Ratner, Guillermina Stevens, Maria Marta Bonaventura, Victoria A Lux-Lantos, Matti Poutanen, Ricardo S Calandra, Ilpo T Huhtaniemi, Susana B Rull. Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice. The Journal of endocrinology. vol 230. issue 1. 2017-06-13. PMID:27154336. |
a 1-week treatment with the dopamine agonist cabergoline applied on 5-week-old hcgβ+ mice, which corrected hyperprolactinemia, hyperandrogenism, and hyperprogesteronemia, effectively prevented the metabolic alterations. |
2017-06-13 |
2023-08-13 |
mouse |
| Yusuke Iwata, Shinichiro Nakajima, Fernando Caravaggio, Takefumi Suzuki, Hiroyuki Uchida, Eric Plitman, Jun Ku Chung, Wanna Mar, Philip Gerretsen, Bruce G Pollock, Benoit H Mulsant, Tarek K Rajji, David C Mamo, Ariel Graff-Guerrer. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. The Journal of clinical psychiatry. vol 77. issue 12. 2017-06-05. PMID:28086010. |
threshold of dopamine d2/3 receptor occupancy for hyperprolactinemia in older patients with schizophrenia. |
2017-06-05 |
2023-08-13 |
human |
| Yusuke Iwata, Shinichiro Nakajima, Fernando Caravaggio, Takefumi Suzuki, Hiroyuki Uchida, Eric Plitman, Jun Ku Chung, Wanna Mar, Philip Gerretsen, Bruce G Pollock, Benoit H Mulsant, Tarek K Rajji, David C Mamo, Ariel Graff-Guerrer. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. The Journal of clinical psychiatry. vol 77. issue 12. 2017-06-05. PMID:28086010. |
although hyperprolactinemia carries a long-term risk of morbidity, the threshold of dopamine d2/3 receptor (d2/3r) occupancy for hyperprolactinemia has not been investigated in older patients with schizophrenia. |
2017-06-05 |
2023-08-13 |
human |
| E Sala, P Bellaviti Buttoni, E Malchiodi, E Verrua, G Carosi, E Profka, G Rodari, M Filopanti, E Ferrante, A Spada, G Mantovan. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. Journal of endocrinological investigation. vol 39. issue 12. 2017-04-25. PMID:27245604. |
recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. |
2017-04-25 |
2023-08-13 |
Not clear |
| Sema Ciftci Dogansen, Ozlem Soyluk Selcukbiricik, Seher Tanrikulu, Sema Yarma. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? Pituitary. vol 19. issue 3. 2017-03-22. PMID:26830552. |
the aim of the study was to assess the effect of dopamine agonist (da) withdrawal, the current recurrence rate of hyperprolactinemia, and possible factors that predict recurrence in patients with prolactinoma. |
2017-03-22 |
2023-08-13 |
Not clear |
| A U Kurina, T S Pronina, L K Dilmukhametova, G V Maleev, M V Ugrumo. Cooperative Synthesis of Dopamine in Rat Mediobasal Hypothalamus as a Compensatory Mechanism in Hyperprolactinemia. Biochemistry. Biokhimiia. vol 82. issue 3. 2017-03-22. PMID:28320278. |
cooperative synthesis of dopamine in rat mediobasal hypothalamus as a compensatory mechanism in hyperprolactinemia. |
2017-03-22 |
2023-08-13 |
rat |
| Virgilio Melgar, Etual Espinosa, Ernesto Sosa, María José Rangel, Dalia Cuenca, Claudia Ramírez, Moisés Mercad. [Current diagnosis and treatment of hyperprolactinemia]. Revista medica del Instituto Mexicano del Seguro Social. vol 54. issue 1. 2017-02-07. PMID:26820213. |
once physiological causes such as pregnancy, systemic disorders such as primary hypothyroidism and the use of drugs with dopamine antagonistic actions such as metochlopramide have been ruled out, the most common cause of hyperprolactinemia is a prl-secreting pituitary adenoma or prolactinoma. |
2017-02-07 |
2023-08-13 |
Not clear |
| Anatoly Nikolaev, Cassann N Blake, Diane L Carlso. Association between Hyperprolactinemia and Granulomatous Mastitis. The breast journal. vol 22. issue 2. 2016-12-13. PMID:26705962. |
although most gm cases show association with lactation and pregnancy, a minority of cases have been linked to hyperprolactinemia caused by either dopamine antagonist medications or with intracranial lesions, such as pituitary adenoma. |
2016-12-13 |
2023-08-13 |
Not clear |
| Hengxi Chen, Jing Fu, Wei Huan. Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history. The Cochrane database of systematic reviews. vol 7. 2016-09-21. PMID:27455388. |
dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history. |
2016-09-21 |
2023-08-13 |
Not clear |
| Yongkai Cao, Chengchun Min, Srijan Acharya, Kyeong-Man Kim, Seung Hoon Cheo. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands. Bioorganic & medicinal chemistry. vol 24. issue 2. 2016-08-22. PMID:26707842. |
several d3r-selective modulators over the dopamine d2 receptor (d2r) can avoid extrapyramidal symptoms (eps) and hyperprolactinemia. |
2016-08-22 |
2023-08-13 |
Not clear |
| Susan L Samson, Shereen Ezza. AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 20. issue 6. 2016-08-05. PMID:24969114. |
aace/ace disease state clinical review: dopamine agonists for hyperprolactinemia and the risk of cardiac valve disease. |
2016-08-05 |
2023-08-13 |
Not clear |
| Christopher D'Sylva, Tayyab Khan, Stan Van Uum, Lisa-Ann Frase. Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis. Neuro endocrinology letters. vol 36. issue 8. 2016-07-15. PMID:26921574. |
osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: a systematic review and meta-analysis. |
2016-07-15 |
2023-08-13 |
Not clear |
| Rabia Nazik Yüksel, Zeynep Elyas Kaya, Nesrin Dilbaz, Merve Cingi Yirü. Cabergoline-induced manic episode: case report. Therapeutic advances in psychopharmacology. vol 6. issue 3. 2016-06-29. PMID:27354910. |
cabergoline is an orally administered synthetic dopamine agonist that is used for the treatment of hyperprolactinemia, parkinson's disease and antipsychotic-induced prolactin elevation. |
2016-06-29 |
2023-08-13 |
Not clear |